EA201891099A1 - 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7 - Google Patents
7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7Info
- Publication number
- EA201891099A1 EA201891099A1 EA201891099A EA201891099A EA201891099A1 EA 201891099 A1 EA201891099 A1 EA 201891099A1 EA 201891099 A EA201891099 A EA 201891099A EA 201891099 A EA201891099 A EA 201891099A EA 201891099 A1 EA201891099 A1 EA 201891099A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- agonist
- pyrrolopyrimide
- tiazol
- tlr7 receptor
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к соединению 7-(тиазол-5-ил)пирролопиримидина в качестве агониста TLR7, в частности относится к соединению, показанному в формуле (I), его фармацевтически приемлемой соли и способу его получения, фармацевтической композиции, содержащей такое соединение, и их применению в изготовлении противовирусного лекарственного средства.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510744651 | 2015-11-05 | ||
PCT/CN2016/104644 WO2017076346A1 (zh) | 2015-11-05 | 2016-11-04 | 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201891099A1 true EA201891099A1 (ru) | 2018-10-31 |
EA035116B1 EA035116B1 (ru) | 2020-04-29 |
Family
ID=58662470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201891099A EA035116B1 (ru) | 2015-11-05 | 2016-11-04 | 7-(тиазол-5-ил)пирролопиримидин в качестве агониста рецептора tlr7 |
Country Status (22)
Country | Link |
---|---|
US (1) | US10676478B2 (ru) |
EP (1) | EP3381918B1 (ru) |
JP (1) | JP6524355B2 (ru) |
KR (1) | KR102112192B1 (ru) |
CN (1) | CN108349982B (ru) |
AU (1) | AU2016349080B2 (ru) |
BR (1) | BR112018008880B1 (ru) |
CA (1) | CA3004173C (ru) |
CL (1) | CL2018001207A1 (ru) |
DK (1) | DK3381918T3 (ru) |
EA (1) | EA035116B1 (ru) |
ES (1) | ES2833927T3 (ru) |
HK (1) | HK1250983A1 (ru) |
HU (1) | HUE052770T2 (ru) |
IL (1) | IL259115B (ru) |
MX (1) | MX2018005708A (ru) |
MY (1) | MY189991A (ru) |
NZ (1) | NZ742453A (ru) |
PH (1) | PH12018500975A1 (ru) |
SG (1) | SG11201803699YA (ru) |
UA (1) | UA121345C2 (ru) |
WO (1) | WO2017076346A1 (ru) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Transgenic meganonucleases specific for recognition sequences in the hepatitis B virus genome |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
CN112105620A (zh) | 2018-05-25 | 2020-12-18 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的tlr7激动剂及其药物组合 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
CA3116137A1 (en) | 2018-10-12 | 2020-04-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tlr7 agonist for treating colorectal cancer and pharmaceutical combination thereof |
TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途 |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020188448A1 (en) * | 2019-03-15 | 2020-09-24 | Janssen Sciences Ireland Unlimited Company | Toll-like receptor agonists for use in the treatment of hepatitis b |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
US20230015906A1 (en) * | 2019-09-29 | 2023-01-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Drug combination containing tlr7 agonist |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
US20230118688A1 (en) | 2020-01-27 | 2023-04-20 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
EP4097104A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
WO2021154662A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
CN115279765A (zh) | 2020-01-27 | 2022-11-01 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
US20230041738A1 (en) | 2020-01-27 | 2023-02-09 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
US20230131192A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
US20230130516A1 (en) | 2020-01-27 | 2023-04-27 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
KR20220132593A (ko) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물 |
WO2021154667A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
CN115666637A (zh) | 2020-03-02 | 2023-01-31 | 蛋白科技先锋 | 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法 |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
EP4194006A1 (en) | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
WO2022031011A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 동력학적으로 작용하는 아주번트 앙상블 |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
EP4316518A1 (en) | 2021-03-29 | 2024-02-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Drug combination of toll-like receptor 7 agonist and anti-pd-l1 antibody |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2577514T3 (es) | 2005-08-22 | 2016-07-15 | The Regents Of The University Of California | Antagonistas de TLR |
KR101687841B1 (ko) | 2008-12-09 | 2016-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체의 조절제 |
CN104780922B (zh) * | 2012-11-20 | 2016-09-07 | 葛兰素史克有限责任公司 | 干扰素诱导剂化合物 |
CN104780924B (zh) | 2012-11-20 | 2016-09-14 | 葛兰素史克有限责任公司 | 干扰素诱导剂化合物 |
CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
US9962388B2 (en) * | 2014-08-15 | 2018-05-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
-
2016
- 2016-11-04 MY MYPI2018701754A patent/MY189991A/en unknown
- 2016-11-04 EA EA201891099A patent/EA035116B1/ru unknown
- 2016-11-04 MX MX2018005708A patent/MX2018005708A/es active IP Right Grant
- 2016-11-04 KR KR1020187015405A patent/KR102112192B1/ko active IP Right Grant
- 2016-11-04 CN CN201680064165.2A patent/CN108349982B/zh active Active
- 2016-11-04 CA CA3004173A patent/CA3004173C/en active Active
- 2016-11-04 DK DK16861614.2T patent/DK3381918T3/da active
- 2016-11-04 ES ES16861614T patent/ES2833927T3/es active Active
- 2016-11-04 SG SG11201803699YA patent/SG11201803699YA/en unknown
- 2016-11-04 JP JP2018541478A patent/JP6524355B2/ja active Active
- 2016-11-04 WO PCT/CN2016/104644 patent/WO2017076346A1/zh active Application Filing
- 2016-11-04 BR BR112018008880-3A patent/BR112018008880B1/pt active IP Right Grant
- 2016-11-04 NZ NZ742453A patent/NZ742453A/en unknown
- 2016-11-04 EP EP16861614.2A patent/EP3381918B1/en active Active
- 2016-11-04 UA UAA201806167A patent/UA121345C2/uk unknown
- 2016-11-04 HU HUE16861614A patent/HUE052770T2/hu unknown
- 2016-11-04 US US15/772,995 patent/US10676478B2/en active Active
- 2016-11-04 AU AU2016349080A patent/AU2016349080B2/en active Active
-
2018
- 2018-05-03 IL IL259115A patent/IL259115B/en active IP Right Grant
- 2018-05-04 PH PH12018500975A patent/PH12018500975A1/en unknown
- 2018-05-04 CL CL2018001207A patent/CL2018001207A1/es unknown
- 2018-08-14 HK HK18110395.0A patent/HK1250983A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN108349982A (zh) | 2018-07-31 |
EP3381918B1 (en) | 2020-09-16 |
UA121345C2 (uk) | 2020-05-12 |
US20180370976A1 (en) | 2018-12-27 |
ES2833927T3 (es) | 2021-06-16 |
CN108349982B (zh) | 2020-05-05 |
US10676478B2 (en) | 2020-06-09 |
IL259115B (en) | 2020-09-30 |
PH12018500975A1 (en) | 2019-01-28 |
BR112018008880B1 (pt) | 2023-01-17 |
CL2018001207A1 (es) | 2018-12-21 |
JP2018536702A (ja) | 2018-12-13 |
WO2017076346A1 (zh) | 2017-05-11 |
DK3381918T3 (da) | 2020-11-09 |
HK1250983A1 (zh) | 2019-01-18 |
KR102112192B1 (ko) | 2020-05-19 |
CA3004173A1 (en) | 2017-05-11 |
EP3381918A1 (en) | 2018-10-03 |
JP6524355B2 (ja) | 2019-06-05 |
MX2018005708A (es) | 2018-11-09 |
SG11201803699YA (en) | 2018-06-28 |
AU2016349080A1 (en) | 2018-05-31 |
BR112018008880A2 (pt) | 2018-11-06 |
KR20180073676A (ko) | 2018-07-02 |
EP3381918A4 (en) | 2019-04-03 |
AU2016349080B2 (en) | 2019-03-14 |
MY189991A (en) | 2022-03-22 |
CA3004173C (en) | 2020-07-14 |
HUE052770T2 (hu) | 2021-05-28 |
BR112018008880A8 (pt) | 2019-02-26 |
EA035116B1 (ru) | 2020-04-29 |
IL259115A (en) | 2018-06-28 |
NZ742453A (en) | 2019-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891099A1 (ru) | 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7 | |
PH12020551089A1 (en) | Pyrrolopyrimidine compounds used as tlr7 agonist | |
PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
EA201790949A1 (ru) | Замещенные 2,4-диаминохинолины в качестве новых противораковых средств | |
EA201490222A1 (ru) | Комбинированные составы на основе дарунавира | |
EA201990388A1 (ru) | Пиперидиновые модуляторы рецепторов cxcr7 | |
EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
EA201490223A1 (ru) | Составы на основе дарунавира | |
EA201890532A1 (ru) | Новые аннелированные бензамиды | |
EA201501163A1 (ru) | Модуляторы рецептора cxcr7 | |
EA201692298A1 (ru) | Производные карбоксамидов | |
EA201692300A1 (ru) | Производные карбоксамида | |
EA201990656A1 (ru) | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 | |
EA201891136A1 (ru) | Фармацевтическая композиция, содержащая в качестве активного ингредиента производное 7-азаиндолин-2-она или его фармацевтически приемлемую соль | |
GR1008380B (el) | Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου |